{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:09:56Z","timestamp":1789992596974,"version":"4.0.1"},"reference-count":34,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Psoriasis is a chronic immune-mediated inflammatory disease that often requires long-term systemic therapy. Coexisting human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection complicates treatment selection because clinicians must balance control of skin and joint inflammation against risks of opportunistic infection, viral replication or reactivation, hepatotoxicity, and drug interactions. Materials and Methods: This narrative review summarizes evidence from guidelines, systematic reviews, cohort studies, case series, expert recommendations, and regulatory sources. Results: In patients with suppressed HIV RNA, stable or reconstituted CD4 counts, no active opportunistic infection, and reliable follow-up, selected systemic agents, including biologics, may be considered after individualized risk assessment. In HBV infection, reactivation prevention through antiviral prophylaxis or close monitoring is central. In HCV infection, fibrosis stage, active hepatitis, drug interactions, and timing of direct-acting antivirals should guide management. Conclusions: Chronic viral infection should not be regarded as an absolute barrier to modern psoriasis therapy.<\/jats:p>","DOI":"10.3390\/medicina62091796","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:25:43Z","timestamp":1789986343000},"page":"1796","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psoriasis and Chronic Viral Infections (HIV, HBV, and HCV): Therapeutic Approach and Safety"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0669-5366","authenticated-orcid":false,"given":"Gustavo","family":"Almeida-Silva","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Avenida Prof. Egas Moniz, 1649-035 Lisbon, Portugal"},{"name":"Dermatology University Clinic, Faculty of Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Couto-Sousa","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Department, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisbon, Portugal"},{"name":"Gastroenterology and Hepatology University Clinic, Faculty of Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Tribolet-Abreu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Avenida Prof. Egas Moniz, 1649-035 Lisbon, Portugal"},{"name":"Dermatology University Clinic, Faculty of Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Avenida Prof. Egas Moniz, 1649-035 Lisbon, Portugal"},{"name":"Dermatology University Clinic, Faculty of Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Dermatology University Clinic, Faculty of Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Antunes","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Avenida Prof. Egas Moniz, 1649-035 Lisbon, Portugal"},{"name":"Dermatology University Clinic, Faculty of Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Filipe","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Avenida Prof. Egas Moniz, 1649-035 Lisbon, Portugal"},{"name":"Dermatology University Clinic, Faculty of Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","unstructured":"U.S. Food and Drug Administration (2026). ICOTYDE (Icotrokinra) Tablets, for Oral Use: Prescribing Information."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40257-026-01019-0","article-title":"Icotrokinra: An oral interleukin-23 receptor antagonist peptide for the treatment of psoriasis","volume":"27","author":"Ferreira","year":"2026","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa2504187","article-title":"Oral icotrokinra for plaque psoriasis in adults and adolescents","volume":"393","author":"Bissonnette","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(25)01576-4","article-title":"Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): Two phase 3, randomized, placebo-controlled and active-comparator-controlled trials","volume":"406","author":"Gold","year":"2025","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1473-3099(10)70101-8","article-title":"HIV-associated psoriasis: Pathogenesis, clinical features, and management","volume":"10","author":"Morar","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jaad.2009.03.047","article-title":"Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation","volume":"62","author":"Menon","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0956462419827673","article-title":"Psoriasis in HIV infection: An update","volume":"30","author":"Filipe","year":"2019","journal-title":"Int. J. STD AIDS"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_13","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 83, 502\u2013583."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA Clinical Practice Guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: Current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s13555-022-00682-5","article-title":"Risk for hepatitis B virus reactivation in patients with psoriasis treated with biological agents: A systematic review and meta-analysis","volume":"12","author":"Wang","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"ref_20","unstructured":"Bhattacharya, D., Aronsohn, A., Price, J., Lo Re, V., and AASLD-IDSA HCV Guidance Panel (2023). Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40257-019-00457-3","article-title":"Managing psoriasis in patients with HBV or HCV infection: Practical considerations","volume":"20","author":"Piaserico","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s12325-024-02873-2","article-title":"Management of psoriasis patients with serious infectious diseases","volume":"41","author":"Megna","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections","volume":"80","author":"Kaushik","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s13555-022-00722-0","article-title":"Use of systemic therapies for treatment of psoriasis in people living with controlled HIV: Inference-based guidance from a multidisciplinary expert panel","volume":"12","author":"Papp","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kuo, M.H., Tsai, T.F., and Chiu, H.Y. (2025). Incidence of HBV reactivation in psoriasis patients receiving cytokine inhibitors: A retrospective cohort study and meta-analysis. Viruses, 17.","DOI":"10.3390\/v17010042"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaad.2013.08.049","article-title":"Recommendations for screening for hepatitis B infection prior to initiating anti-TNF-alpha inhibitors or other immunosuppressive agents in patients with psoriasis","volume":"70","author":"Motaparthi","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/2475530320954279","article-title":"Biologic treatment of 4 HIV-positive patients: A case series and literature review","volume":"6","author":"Myers","year":"2021","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/jdv.19020","article-title":"The impact of psoriasis biologic therapy on HIV viral load and CD4+ cell counts in HIV-positive individuals: A real-world cohort study","volume":"37","author":"Xu","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shimon, S.V., and Romanelli, P. (2025). Systematic review of biologic use for psoriasis in HIV-positive individuals from 2018 to 2024. Arch. Dermatol. Res., 317.","DOI":"10.1007\/s00403-024-03395-1"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10238-022-00827-y","article-title":"Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: A systematic review and meta-analysis","volume":"23","author":"Li","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: A multicentre prospective cohort study","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40261-022-01163-5","article-title":"Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real-world setting of hepatitis B or hepatitis C infection","volume":"42","author":"Megna","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"ref_34","first-page":"1","article-title":"The use of interleukin 23 inhibitors in patients with chronic hepatitis B infection: A case series","volume":"30","author":"Farrer","year":"2022","journal-title":"JAAD Case Rep."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1796\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:26:28Z","timestamp":1789989988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medicina62091796"],"URL":"https:\/\/doi.org\/10.3390\/medicina62091796","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}